Skip to content
Back to the Guavy Wire
Forex

Prime Medicine Shares Drop 7.6% Amid Mixed Analyst Sentiment

Instruments
CHF CAD
Share

Prime Medicine (NASDAQ:PRME) saw its share price drop 7.6% during mid-day trading on Tuesday, November 17, 2026. The stock hit a low of $3.90 and closed at $3.8710, with trading volume declining 9% from its average session volume. The company had previously closed at $4.19.

Several research firms have recently commented on Prime Medicine. Jefferies Financial Group and Citigroup both reaffirmed a market outperform rating. Chardan Capital and HC Wainwright issued buy ratings with target prices of $7.00 and $8.00, respectively. Wall Street Zen upgraded the stock from a sell to a hold rating. The stock currently has a consensus rating of Moderate Buy and a consensus target price of $7.86.

Prime Medicine reported its quarterly earnings on November 12, 2026, posting a loss of $0.22 per share, which beat analysts' estimates of $0.23. The company had revenue of $4.21 million for the quarter. Analysts expect Prime Medicine to post -$0.97 EPS for the current fiscal year.

Institutional investors have been active in adjusting their holdings. Arizona State Retirement System, China Universal Asset Management, Royal Bank of Canada, and Swiss National Bank all increased their stakes in the company. Mirae Asset Global Investments initiated a new position in the third quarter. Institutional investors now own 70.37% of the stock.

More on Forex